S
Susan Mather
Researcher at Pfizer
Publications - 10
Citations - 11400
Susan Mather is an academic researcher from Pfizer. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 4, co-authored 5 publications receiving 4459 citations.
Papers
More filters
Journal ArticleDOI
Evaluation of BNT162b2 Covid-19 Vaccine in Children Younger than 5 Years of Age
Flor M. Munoz,Lawrence Sher,Charu Sabharwal,Alejandra Gurtman,Xia Xu,Nicholas Kitchin,Stephen Lockhart,Robert Riesenberg,Joanna M Sexter,Hanna Czajka,Grant Paulsen,Yvonne Maldonado,Emmanuel B. Walter,Kawsar R. Talaat,Janet A. Englund,Uzma N. Sarwar,Caitlin Hansen,Martha Iwamoto,Chris Webber,Luke Cunliffe,Benita Ukkonen,Silvina N Martínez,Barbara A. Pahud,Iona Munjal,Joseph B. Domachowske,Kena A. Swanson,Hua Ma,Kenneth Koury,Susan Mather,Claire M. Lu,Jing Zou,Xuping Xie,Pei Yong Shi,David A. Cooper,Özlem Türeci,Ugur Sahin,Kathrin U. Jansen,William C. Gruber +37 more
TL;DR: A phase 1 dose-finding study and an ongoing phase 2-3 safety, immunogenicity, and efficacy trial of the BNT162b2 vaccine in healthy children 6 months to 11 years of age was conducted in this article .
Journal ArticleDOI
Safety data from the MenB-FHbp clinical development program in healthy individuals aged 10 years and older.
Johannes Beeslaar,Susan Mather,Judith Absalon,Joseph Eiden,Laura J. York,Graham Crowther,Roger Maansson,Jason D. Maguire,Paula Peyrani,John L. Perez +9 more
TL;DR: MenB-FHBP vaccine (Trumenba®) is licensed in various countries for the prevention of meningococcal serogroup B disease in individuals ≥ 10 years of age as discussed by the authors .
Journal ArticleDOI
Clinical trial and postmarketing safety experience with MenACWY-TT, a meningococcal group A, C, W, and Y tetanus conjugate vaccine.
TL;DR: MenACWY-TT is licensed in more than 80 countries worldwide for the prevention of meningococcal disease caused by serogroups A, C, W, and Y in individuals throughout their lifespans as discussed by the authors .
Journal ArticleDOI
Plain language summary of Pfizer-BioNTech BNT162b2 COVID-19 vaccine safety in participants 16 years or older and protection against COVID-19 in participants 12 years or older
Stephen J. Thomas,Edson D. Moreira,Nicholas Kitchin,Judith Absalon,Alejandra Gurtman,Stephen Lockhart,John L. Perez,Gonzalo Pérez Marc,Fernando P. Polack,Cristiano A. F. Zerbini,Ruth Bailey,Kena A. Swanson,Xia Xu,Satrajit Roychoudhury,Kenneth Koury,Salim Bouguermouh,Warren Kalina,David A. Cooper,Robert W. Frenck,Laura L. Hammitt,Özlem Türeci,Haylene Nell,Axel Schaefer,Serhat Ünal,Qi Yang,Paul A. Liberator,Dina B. Tresnan,Susan Mather,Philip R. Dormitzer,Ugur Sahin,William C. Gruber,Kathrin U. Jansen +31 more
TL;DR: A clinical study for the BNT162b2 COVID-19 vaccine, also called the Pfizer-BioNTech vaccine, was conducted in South Africa as discussed by the authors , where participants were given two injections of either the vaccine or a placebo, 21 days apart.
Journal ArticleDOI
Plain language summary of Pfizer-BioNTech BNT162b2 vaccine protection against COVID-19 and its safety in participants 12- to 15-years-old
Robert W. Frenck,Nicola P. Klein,Nicholas Kitchin,Alejandra Gurtman,Judith Absalon,Stephen Lockhart,John L. Perez,Emmanuel B. Walter,Shelly Senders,Ruth Bailey,Kena A. Swanson,Hua Ma,Xia Xu,Kenneth Koury,Warren Kalina,David A. Cooper,Timothy W Jennings,Donald Brandon,Stephen J. Thomas,Özlem Türeci,Dina B. Tresnan,Susan Mather,Philip R. Dormitzer,Ugur Sahin,Kathrin U. Jansen,William C. Gruber +25 more
TL;DR: In this paper , the BNT162b2 COVID-19 vaccine was used to prevent SARS-CoV-2 infections in participants who received the vaccine compared to those who did not.